We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $352M
1-Year Est. Return 220.14%
This Fund
S&P 500
This Quarter Est. Return
-17.44%
1 Year Est. Return
+220.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
-$155M
Cap. Flow
-$29.7M
Cap. Flow %
-8.45%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$25.7M
2
CAMP icon
CAMP4 Therapeutics
CAMP
+$4.01M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SION
1
Sionna Therapeutics
SION
$2.13B
$99.3M 28.26%
2,478,030
– –
IMNM icon
2
Immunome
IMNM
$2.58B
$79M 22.48%
3,613,799
-1,154,784
-24% -$25.7M
ZBIO
3
Zenas BioPharma
ZBIO
$1.98B
$76.6M 21.8%
3,919,159
– –
CMPX icon
4
Compass Therapeutics
CMPX
$344M
$41.2M 11.72%
7,788,150
– –
BBOT
5
BridgeBio Oncology
BBOT
$648M
$23.5M 6.69%
2,626,946
– –
UPB
6
Upstream Bio Inc
UPB
$343M
$22.1M 6.3%
2,459,703
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$179M
$9.66M 2.75%
2,190,920
-844,905
-28% -$4.01M

Similar funds

HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
FFO
Fiduciary Family Office Boca Raton, Florida $351M AUM 22.19% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Enavate Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, Enavate Sciences held 7 positions worth $352M, down 31% from $507M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Enavate Sciences withdrew a net $29.7M in Q1 2026, reducing 2 holdings. Its largest reduction was Immunome, cutting an estimated $25.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences's biggest Q1 2026 reduction was Immunome, cutting an estimated $25.7M.
  • Enavate Sciences's ten largest holdings make up 100% of its $352M portfolio in Q1 2026.
  • Enavate Sciences opened 0 new positions and closed 0 in Q1 2026.
  • Enavate Sciences's portfolio value fell 31% quarter-over-quarter to $352M.

Based on Enavate Sciences's 13F filing for Q1 2026, filed 15 May 2026.